Cordlife Group Ltd. is an investment holding company, which engages in the provision of cord blood and cord lining banking services. The firm's principal activities involve investment holding and the provision of cord blood banking services. Its segments include Banking and Diagnostics. The Banking segment comprises of the banking of samples such as cord blood, cord lining and cord tissue. Cord blood, cord lining and cord tissue are collected, processed, and stored in the various laboratories. The Diagnostics segment comprises diagnostic testing such as non-invasive prenatal testing service, newborn metabolic screening, newborn genetic screening, and pediatric vision screening services. Its subsidiaries include Cordlife (Hong Kong) Limited, Cordlife Stem Cell Technology Limited, Healthbaby Biotech (Hong Kong) Co., Limited, Cordlife Technologies Pte. Ltd., CS Cell Technologies Pte. Ltd., Stemlife Berhad, and Shanghai Cordlife Biomedical Research Co., Ltd.
CLIFF stock price ended at $0.07 on 火曜日, after rising 0.00%
On the latest trading day Mar 31, 2026, the stock price of CLIFF rose by 0.00%, climbing from $0.07 to $0.07. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.07 and a high of $0.07. Notably, trading volume dropped by 1.1K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 2.1K shares were traded, equating to a market value of approximately $17.9M.